| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell and Tumor Biology |
1 Dipartimento di Medicina Interna e di Medicina Specialistica, Cattedra di Endocrinologia, University of Catania, Ospedale Garibaldi, Catania, Italy; 2 Department of Pediatrics, Oregon Health and Science University, Portland, Oregon; 3 Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine and Veterans Affairs Medical Center, Houston, Texas; and 4 Dipartimento di Medicina Sperimentale e Clinica, Cattedra di Endocrinologia, Policlinico Mater Domini, University of Catanzaro "Magna Graecia," Catanzaro, Italy
Requests for reprints: Antonino Belfiore, Dipartimento di Medicina Sperimentale e Clinica, Cattedra di Endocrinologia, Policlinico Mater Domini, University of Catanzaro "Magna Graecia," via T. Campanella 115, 88100 Catanzaro, Italy. Phone: 39-961-712-423; Fax: 39-961-772-748; E-mail: belfiore{at}unicz.it.
In this study, we show that androgens up-regulate insulin-like growth factor-I receptor (IGF-IR) expression and sensitize prostate cancer cells to the biological effects of IGF-I. Both dihydrotestosterone and the synthetic androgen R1881 induced an
6-fold increase in IGF-IR expression in androgen receptor (AR)positive prostate cancer cells LNCaP. In accordance with IGF-IR up-regulation, treatment with the nonmetabolizable androgen R1881 sensitized LNCaP cells to the mitogenic and motogenic effects of IGF-I, whereas an IGF-IR blocking antibody effectively inhibited these effects. By contrast, these androgens did not affect IGF-IR expression in AR-negative prostate cancer cells PC-3. Reintroduction of AR into PC-3 cells by stable transfection restored the androgen effect on IGF-IR up-regulation. R1881-induced IGF-IR up-regulation was partially inhibited by the AR antagonist Casodex (bicalutamide). Two other AR antagonists, cyproterone acetate and OH-flutamide, were much less effective. Androgen-induced IGF-IR up-regulation was not dependent on AR genomic activity, because two AR mutants, AR-C619Y and AR-C574R, devoid of DNA binding activity and transcriptional activity were still able to elicit IGF-IR up-regulation in HEK293 kidney cells in response to androgens. Moreover, androgen-induced IGF-IR up-regulation involves the activation of the Src-extracellular signal-regulated kinase pathway, because it was inhibited by both the Src inhibitor PP2 and the MEK-1 inhibitor PD98059. The present observations strongly suggest that AR activation may stimulate prostate cancer progression through the altered IGF-IR expression and IGF action. Anti-androgen therapy may be only partially effective, or almost ineffective, in blocking important biological effects of androgens, such as activation of the IGF system.
Key Words: Androgen IGF system IGF-I receptor Insulin receptor Prostate cancer
This article has been cited by other articles:
![]() |
A. Belfiore, F. Frasca, G. Pandini, L. Sciacca, and R. Vigneri Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease Endocr. Rev., October 1, 2009; 30(6): 586 - 623. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Genua, G. Pandini, D. Sisci, G. Castoria, M. Maggiolini, R. Vigneri, and A. Belfiore Role of Cyclic AMP Response Element-Binding Protein in Insulin-like Growth Factor-I Receptor Up-regulation by Sex Steroids in Prostate Cancer Cells Cancer Res., September 15, 2009; 69(18): 7270 - 7277. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Frigo, A. B. Sherk, B. M. Wittmann, J. D. Norris, Q. Wang, J. D. Joseph, A. P. Toner, M. Brown, and D. P. McDonnell Induction of Kruppel-Like Factor 5 Expression by Androgens Results in Increased CXCR4-Dependent Migration of Prostate Cancer Cells in Vitro Mol. Endocrinol., September 1, 2009; 23(9): 1385 - 1396. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. X. Zou, L. Guo, A. S. Revenko, C. G. Tepper, A. T. Gemo, H.-J. Kung, and H.-W. Chen Androgen-Induced Coactivator ANCCA Mediates Specific Androgen Receptor Signaling in Prostate Cancer Cancer Res., April 15, 2009; 69(8): 3339 - 3346. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Svensson, J. Kindblom, R. Shao, S. Moverare-Skrtic, M. K Lagerquist, N. Andersson, K. Sjogren, K. Venken, D. Vanderschueren, J.-O. Jansson, et al. Liver-derived IGF1 enhances the androgenic response in prostate J. Endocrinol., December 1, 2008; 199(3): 489 - 497. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-Y. Wu, K. Chen, B. Haendler, T. V. McDonald, and J.-S. Bian Stimulation of N-Terminal Truncated Isoform of Androgen Receptor Stabilizes Human Ether-a-go-go-Related Gene-Encoded Potassium Channel Protein via Activation of Extracellular Signal Regulated Kinase 1/2 Endocrinology, October 1, 2008; 149(10): 5061 - 5069. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Goldman-Johnson, D. M. de Kretser, and J. R. Morrison Evidence that Androgens Regulate Early Developmental Events, Prior to Sexual Differentiation Endocrinology, January 1, 2008; 149(1): 5 - 14. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Venkateswaran, A. Q. Haddad, N. E. Fleshner, R. Fan, L. M. Sugar, R. Nam, L. H. Klotz, and M. Pollak Association of Diet-Induced Hyperinsulinemia With Accelerated Growth of Prostate Cancer (LNCaP) Xenografts J Natl Cancer Inst, December 5, 2007; 99(23): 1793 - 1800. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Fizazi The role of Src in prostate cancer Ann. Onc., November 1, 2007; 18(11): 1765 - 1773. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Cinar, N. K. Mukhopadhyay, G. Meng, and M. R. Freeman Phosphoinositide 3-Kinase-independent Non-genomic Signals Transit from the Androgen Receptor to Akt1 in Membrane Raft Microdomains J. Biol. Chem., October 5, 2007; 282(40): 29584 - 29593. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhang, J. Wang, B. Pang, R.-x. Liang, S. Li, P.-t. Huang, R. Wang, L. W.K. Chung, H. E. Zhau, C. Huang, et al. PC-1/PrLZ Contributes to Malignant Progression in Prostate Cancer Cancer Res., September 15, 2007; 67(18): 8906 - 8913. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Pandini, M. Genua, F. Frasca, S. Squatrito, R. Vigneri, and A. Belfiore 17{beta}-Estradiol Up-regulates the Insulin-like Growth Factor Receptor through a Nongenotropic Pathway in Prostate Cancer Cells Cancer Res., September 15, 2007; 67(18): 8932 - 8941. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Chen, R. Freeman, L. F. Voigt, A. Fitzpatrick, S. R. Plymate, and N. S. Weiss Prostate Cancer Risk in Relation to Selected Genetic Polymorphisms in Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-3, and Insulin-like Growth Factor-I Receptor Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2461 - 2466. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yakar, N. P. Nunez, P. Pennisi, P. Brodt, H. Sun, L. Fallavollita, H. Zhao, L. Scavo, R. Novosyadlyy, N. Kurshan, et al. Increased Tumor Growth in Mice with Diet-Induced Obesity: Impact of Ovarian Hormones Endocrinology, December 1, 2006; 147(12): 5826 - 5834. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kawada, H. Inoue, T. Masuda, and D. Ikeda Insulin-like Growth Factor I Secreted from Prostate Stromal Cells Mediates Tumor-Stromal Cell Interactions of Prostate Cancer. Cancer Res., April 15, 2006; 66(8): 4419 - 4425. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Khosla, L. J. Melton III, S. J. Achenbach, A. L. Oberg, and B. L. Riggs Hormonal and Biochemical Determinants of Trabecular Microstructure at the Ultradistal Radius in Women and Men J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 885 - 891. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |